pantoprazole has been researched along with Irritable Bowel Syndrome in 5 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Irritable Bowel Syndrome: A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized, double-blind, placebo-controlled study, patients with typical gastroesophageal reflux disease symptoms receiving pantoprazole 40 mg/d for six months were randomly assigned to receive: (A) Lactobacillus paracasei F19 bid for three days/week for six months; (B) placebo bid for three days/week for six months; (C) Lactobacillus paracasei F19 bid for three days/week for three months and placebo bid for three days/week for the following three months; (D) placebo bid for three days/week for three months and Lactobacillus paracasei F19 bid for three days/week for the following three months." | 5.20 | Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial. ( Campo, SM; Chiodini, P; Coccoli, P; Compare, D; Larussa, T; Luzza, F; Nardone, G; Nazionale, I; Rocco, A; Sgamato, C, 2015) |
| "To investigate the influence of irritable bowel syndrome (IBS)-like symptoms on treatment outcomes with pantoprazole in gastroesophageal reflux disease (GERD) in a real life setting." | 5.15 | Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease. ( Doerfler, H; Heading, RC; Mönnikes, H; Schmitt, H, 2011) |
| "Gastro-oesophageal reflux disease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are highly prevalent gastrointestinal conditions with accumulating evidence of overlap in patients." | 2.77 | Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease. ( Lühmann, R; Mönnikes, H; Sander, P; Schwan, T; Straszak, A; Theek, C; van Rensburg, C, 2012) |
| "Management of patients with gastro-oesophageal reflux disease (GORD) can be assisted by information predicting the likely response to proton pump inhibitor (PPI) treatment." | 2.76 | Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. ( Heading, RC; Mönnikes, H; Schmitt, H; Tholen, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mönnikes, H | 4 |
| Schwan, T | 2 |
| van Rensburg, C | 2 |
| Straszak, A | 2 |
| Theek, C | 2 |
| Lühmann, R | 2 |
| Sander, P | 2 |
| Tholen, A | 2 |
| Compare, D | 1 |
| Rocco, A | 1 |
| Sgamato, C | 1 |
| Coccoli, P | 1 |
| Campo, SM | 1 |
| Nazionale, I | 1 |
| Larussa, T | 1 |
| Luzza, F | 1 |
| Chiodini, P | 1 |
| Nardone, G | 1 |
| Heading, RC | 2 |
| Schmitt, H | 2 |
| Doerfler, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD[NCT00325676] | Phase 4 | 639 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Real Life: Treatment Response in Patients With Symptoms Due to Gastroesophageal Reflux Disease Either With or Without Esophagitis Treated With Pantoprazole Sodium 40 mg o.d. Over 8 Weeks[NCT00312806] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for pantoprazole and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Esophagitis, Peptic; Female; Gastro | 2013 |
Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Dietary Supple | 2015 |
Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anxiety; Body Mass Index; Female; Gastroesophageal R | 2011 |
Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Comorbidity; Esophagitis; Female; | 2011 |
Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dyspepsia; Female; Gastroesophageal Reflux; Humans; | 2012 |